deucrictibant is a Pharvaris N.V. program. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Sponsor: Pharvaris N.V. (PHVS). Review status: Pharvaris announced positive topline data from the CHAPTER-3 pivotal study of deucrictibant XR for prophylaxis of HAE attacks on September 8, 2026: primary endpoint met, 83% attack-rate reduction versus placebo (6-K exhibit 99.1). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Cormorant Asset Management | 750,000 | $25.9 million | filed August 14, 2026 |
| EcoR1 Capital | 235,000 | $8.1 million | filed August 14, 2026 |
| OrbiMed Advisors | 205,400 | $7.1 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
deucrictibant's most recent tracked catalyst has already reported: positive data on Sep 8, 2026, per the company's own release (linked in the history below). No further catalyst is on our calendar yet.
No FDA decision for deucrictibant is in our archive yet.
Pharvaris N.V. (PHVS).
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.